Recognizing Familial Chylomicronemia Syndrome in the APOC3 Era

Treatment of severe hypertriglyceridemia is shifting as therapies targeting apolipoprotein C-III (APOC3) move into practice. Yet the patients these agents were first approved for, those with familial chylomicronemia syndrome (FCS), are rarely seen outside lipid clinics and often misidentified. For most clinicians, the first challenge is separating a disorder affecting 1 to 19 people per million from far more common multifactorial chylomicronemia.

At a clinical forum held September 24, 2026, in Houston, Texas, Anjori Dunbar, MD, medical director and cardiologist at Heartbeat Health, led participants spanning cardiology, endocrinology, hospital medicine, oncology, and primary care through FCS recognition, standard management, and the APOC3-targeted treatment landscape. The discussion centered on when clinicians should suspect FCS and what changes once they do.

Dunbar described FCS as an autosomal recessive disorder caused by complete or partial loss of lipoprotein lipase (LPL) activity, with biallelic LPL loss-of-function variants accounting for 60% to 80% of cases. Compared with multifactorial chylomicronemia syndrome (MCS), FCS typically presents in childhood, in patients with normal or low body mass index, with persistent rather than intermittent fasting triglyceride levels of 880 mg/dL or higher.¹ Lifetime risk of acute pancreatitis is 60% to 88% in FCS vs 11% to 37% in MCS, and response to statins, fibrates, and omega-3 fatty acids is minimal or absent.¹

In the IN-FOCUS survey of 166 patients with FCS, which Dunbar reviewed, patients saw a mean of five physicians before diagnosis and nearly half were first misdiagnosed.² Two-thirds reported that the condition significantly affected self-worth, emotional well-being, sleep, and mental functioning.²

Participants described a workup that begins with secondary causes, including uncontrolled diabetes, alcohol use, nephrotic syndrome, pregnancy, and medications such as estrogen, diuretics, and HIV antiretrovirals. One participant said apolipoprotein B (apoB) is the first test ordered in that participant's practice, with a triglyceride-to-apoB ratio above 10 flagging chylomicron-driven disease and an apoB below 65 mg/dL pointing toward FCS over MCS. Others said nonresponse to standard triglyceride-lowering therapy, once adherence is confirmed, is often the first clue.

Dunbar reviewed the North American FCS score, which supports a definite clinical diagnosis without genetic testing and, in patients older than 10 years, applies only after triglycerides fail to fall at least 20% on fibrates and omega-3 fatty acids. Participants cited cost and limited insurance coverage of genetic testing as barriers, and one participant reported using the score to diagnose an 18-year-old patient.

Standard care centers on a very-low-fat diet limiting fat to 10% to 15% of calories, alcohol abstinence, and medical-grade medium-chain triglyceride oil when additional calories are needed. Participants described that diet as extremely difficult to sustain, particularly for adolescents.

Dunbar explained that APOC3 inhibition promotes triglyceride clearance through LPL-independent pathways, lowering triglycerides even when LPL activity is absent. Olezarsen, an antisense oligonucleotide given every 4 weeks, and plozasiran, a small interfering RNA given every 3 months, are both FDA approved for FCS.

In the phase 3 BALANCE trial of 66 patients with genetically identified FCS, olezarsen 80 mg reduced triglycerides by 43.5 percentage points vs placebo at 6 months, while the 50-mg dose did not reach significance.³ Pancreatitis was reported as an adverse event in 5% and 10% of patients in the 80-mg and 50-mg groups vs 17% with placebo, and serious adverse events were less frequent with olezarsen.³

The phase 3 PALISADE trial enrolled 75 patients with persistent chylomicronemia, with or without genetic confirmation, and reported median triglyceride reductions of 80% and 78% with plozasiran 25 mg and 50 mg at 10 months vs 17% with placebo.⁴ Dunbar said including patients without genetic confirmation matters because most clinicians are unlikely to establish a genetic diagnosis. Participants noted that neither trial showed the thrombocytopenia seen with an earlier APOC3 inhibitor, though modest transaminase increases warrant monitoring.

One participant reported that a patient treated with olezarsen saw triglycerides fall from the low thousands to about 400 mg/dL, with insurance approval granted without genetic testing and cost driving agent selection. Dunbar said she would target triglycerides below 1000 mg/dL to reduce pancreatitis risk and would check laboratory values at least every 3 months after initiation.

Participants debated whether diet can be relaxed once therapy begins. One participant said triglyceride clearance pathways saturate above roughly 500 mg/dL, so diet remains essential, while others said modest flexibility may matter for adolescents' social lives. The same participant said LDL cholesterol can rise 10% to 20% with APOC3 inhibition, reflecting lipoprotein remodeling rather than added cardiovascular risk.

Dunbar pointed to ongoing study of both agents in severe hypertriglyceridemia beyond FCS, comparing the trajectory to PCSK9 inhibitors, which moved from highest-risk patients to wider use. For community cardiologists and endocrinologists, the forum placed the immediate task in recognition: ordering apoB, excluding secondary causes, and identifying the patient whose triglycerides do not respond to standard therapy.

References

1. Brinton EA, Eckel RH, Gaudet D, et al. Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA. Atherosclerosis. 2025;403:119114. https://doi.org/10.1016/j.atherosclerosis.2025.119114

2. Davidson M, Stevenson M, Hsieh A, et al. The burden of familial chylomicronemia syndrome: results from the global IN-FOCUS study. J Clin Lipidol. 2018;12(4):898-907.e2. https://doi.org/10.1016/j.jacl.2018.04.009

3. Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E, et al. Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome. N Engl J Med. 2024;390(19):1781-1792. https://doi.org/10.1056/NEJMoa2400201

4. Watts GF, Rosenson RS, Hegele RA, et al. Plozasiran for managing persistent chylomicronemia and pancreatitis risk. N Engl J Med. 2025;392(2):127-137. https://doi.org/10.1056/NEJMoa2409368